IP Library › Granted Patent US 8,092,805
Granted Patent B2
US 8,092,805 · App. 12/638,725 · Granted Jan 10, 2012

Dual inhibitors of HIV-1 gp-120 interactions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,092,805
App. No.
12/638,725
Granted
Jan 10, 2012
Kind
B2
Abstract

Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided.

Claims (2)

1. A method of inhibiting the binding of HIV-1 to cell surface receptor CCR5, said method comprising contacting cells infected with HIV-1 with a composition comprising SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 5.

2. A method of inhibiting the HIV-1 fusion process to a cell expressing a CD4 cell surface receptor or a CCR5 cell surface receptor, said method comprising contacting said cell with a composition comprising SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 5.

Assignments (2)
MERGER Recorded Jan 14, 2015
From: PHILADELPHIA HEALTH & EDUCATION CORPORATION
To: DREXEL UNIVERSITY
Reel/Frame 034764/0236 →
CONFIRMATORY LICENSE Recorded Feb 17, 2012
From: DREXEL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027727/0861 →